INTRODUCTION {#s1}
============

Lung cancer patients need accurate and integrated information about risk of recurrence and survival to help with informed decision-making. Traditional survival estimates are given by survival from the time of diagnosis in most reports, representing cumulative survival. However, probabilities of disease recurrence and death evolve over time and usually decline with increased survivorship. As a result, cumulative survival estimates calculated at the time of initial diagnosis have limited utility for follow-up care, since they provide only a static view of risk without postoperative follow-up information and do not reflect changes in prognosis over time.

Conditional survival (CS), derived from the concept of conditional probability, is an estimate of survival probability after having already survived for a specific time after a cancer diagnosis \[[@R1]\]. This estimate of survival is clinically relevant because it reflects the change in survival likelihood with increasing duration of follow-up from the time of the initial cancer diagnosis. CS analysis has been reported for various kinds of malignancies, including ovarian cancer, colon cancer and GIST \[[@R2]--[@R4]\]. Also, some studies comprehensively reported CS of non-small cell lung cancer (NSCLC) without specific focus on lung adenocarcinoma which is the most common histologic type of NSCLC \[[@R5]--[@R8]\].

In this study, we assessed conditional overall survival (OS) and disease-free survival (DFS) among patients with surgically resected stage I-IIIa lung adenocarcinoma and compared the results with traditional survival estimates. Moreover, recently highlighted prognostic factors of lung adenocarcinoma from the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) lung adenocarcinoma classification scheme \[[@R9], [@R10]\] and image biomarkers such as tumor-shadow disappearance ratio (TDR) on CT and maximum standardized uptake value (SUVmax) on 18F-fluoro-2-deoxyglucose (FDG)-PET/CT \[[@R11]\] were evaluated together with traditionally well-known clinico-pathologic factors to identify changes in prognostic contribution over time for each factor.

PATIENTS AND METHODS {#s2}
====================

Our institutional review board approved this retrospective study and informed consent was waived (No. 2015-11-009).

Study population and data collection {#s2_1}
------------------------------------

Eight-hundred and thirty consecutive patients with lung adenocarcinoma were identified between September 2003 and August 2011. All patients underwent complete resection and mediastinal lymph node dissection at Samsung Medical Center (Seoul, Korea) with or without postsurgical adjuvant therapy. Both chest CT and integrated FDG PET/CT were obtained within the month before resection from all patients.

Among these, 68 patients were excluded by prognosis-related factors such as presence of another cancer (43 patients) and micrometastasis at the time of surgery (25 patients). Another 39 patients were excluded due to insufficient pathologic slides for evaluation of the whole tumor. Ultimately, 723 patients (372 males, 351 females; median age, 61 years) were included in this study (Figure A1).

![Three-year conditional overall and disease-free survival estimates](oncotarget-08-32201-g001){#F1}

All cases were staged according to the seventh edition of the TNM classification for lung cancer \[[@R12], [@R13]\]. Pathologic subtyping was carried out according to the criteria of the IASLC/ATS/ERS classification scheme in all cases \[[@R9]\]. For pathologic grading, we adopted a recently proposed system \[[@R10]\] categorizing adenocarcinoma-in-situ, minimally invasive adenocarcinoma and lepidic adenocarcinoma as low grade, acinar and papillary tumor as intermediate grade, and solid and micropapillary tumors as high grade. In addition, according to World Health Organization classification criteria \[[@R14]\], histologic differentiation was categorized into poorly, moderately or well differentiated carcinomas.

Imaging analysis {#s2_2}
----------------

PET/CT imaging was evaluated by a nuclear medicine physician who was unaware of clinical and pathologic data. FDG uptake was evaluated by placing regions of interest and calculated as the SUVmax.

Two chest radiologists were asked to retrospectively evaluate CT scans for maximal diameter of nodules and TDR without clinical information, PET findings, and histologic diagnoses. The longest tumor diameter was measured manually on lung window images of PACS monitors using electronic measurement tools on transverse images. For calculation of TDR \[[@R15]\], the maximum dimension of the tumors and the largest dimension perpendicular to the maximum diameter were measured using both the lung and mediastinal windows. In addition, the observers assessed tumor solidity to visually classify density of the lesions into three categories (non-solid, part-solid, and solid feature) using both lung and mediastinal window settings.

Statistical analysis {#s2_3}
--------------------

To calculate conditional OS and DFS after surgical resection of lung adenocarcinoma, electronic medical records were reviewed for date of last follow-up, documented recurrence, or death. Recurrence was defined as any documented clinical or pathologic evidence of local or distant disease recurrence. DFS was defined as the time from surgery to the first event of recurrence or the last follow up visit. In this study, we evaluated 3-year conditional survival, facilitating prognostication for survivors who have already passed through high risk period of recurrence \[[@R16]--[@R18]\].

Conditional survival probability of time t conditioning at t~0~ is the probability that patients who are alive at time t~0~ survive for additional t. Conditional survival analysis at time t~0~ (≥0) was conducted by applying standard survival analysis methods such as the Kaplan-Meier method, the log-rank test and Cox regression method, to data sets consisting of subjects at risk at time t~0~. Three-year conditional OS and DFS estimates were computed within subgroups defined by performance status, sex, smoking history, stage, pathologic factors, radiologic factors, and history of adjuvant therapy. We also evaluated the contribution of patient characteristics on OS and DFS at baseline and on conditional OS and DFS at 1, 2, 3, 4 and 5 years after surgery using univariable Cox regression models to calculate hazard ratios and corresponding 95% CIs. The size of some of the subgroups and the number of events was too small to yield meaningful results for later years. Furthermore, to determine independent prognostic predictors and to quantify temporal changes of contribution of such predictors on patient prognosis over time, multivariable conditional Cox regression models were fitted at each t~0~ ( = 0, 1, 2, 3, 4, 5 years) using predictors selected with a stepwise method. For a chosen time point t0, we considered the set of all predictor which had been selected for at least one t0 value in order to investigate the time effect of a predictor. Also, the hazard ratio estimates were plotted over the range of t~0~ values. For each significant continuous predictor, a cutoff value was chosen by fitting a conditional univariable Cox regression model for each t~0~ value and finding a value that optimally split all patients into two groups in terms of p-value and hazard ratio in common over different t~0~ values. Conditional 3-year OS and DFS were estimated for each patient group defined by each binary predictor and plotted over different t~0~ values. These analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R 2.10.0 (Vienna, Austria; <http://www.R-project.org>).

RESULTS {#s3}
=======

Baseline demographics and conditional survival analysis {#s3_1}
-------------------------------------------------------

Patient characteristics and radiological features are summarized in the Supplementary Table. After a median follow-up of 3.8 years (range 0.04-9.58 years), 57 (7.8%) patients died (41 and 16 subjects with and without recurrences or metastases, respectively) and 177 (24.48%) recurrences or metastases were recorded after surgical resection. Among all 723 patients included in this study, median OS and DFS were 3.59 years (range, 0.04-9.58 years) and 2.93 years (range, 0.04-9.58), respectively.

The 3-year OS and DFS were 92.12% and 75.52% at baseline, respectively. The probability of surviving an additional 3 years, conditioned on having already survived 1, 2, 3, 4, and 5 years after surgery, improved to 93.40%, 95.68%, 96.09%, 97.43% and 98.33%, respectively. The probability of surviving an additional 3 years without recurrence, conditioned on having already survived 1, 2, 3, 4, and 5 years after surgery, was 80.31%, 87.38%, 92.11%, 94.88% and 95.95%, respectively. Figure [1](#F1){ref-type="fig"} summarizes the conditional probabilities of 3-year OS and DFS for each time point.

Distribution of clinico-pathologic characteristics and stratified conditional survival analysis across years {#s3_2}
------------------------------------------------------------------------------------------------------------

Table [1](#T1){ref-type="table"} shows the distribution of disease and clinical characteristics among patients across years of OS and DFS. In general, the ratio of male sex, ever-smoker, advanced disease stage, high pathologic grade and poor differentiation diminished over time, suggesting that those features correlated to poor OS and DFS. Conversely, proportion of female sex, never-smoker, early disease stage, low pathologic grade and well differentiation gradual increased over time.

###### Distribution of clinico-pathologic characteristics across years of overall (OS) and disease-free survival (DFS)

                           Baseline   1-year   2-year   3-year   4-year   5-year                                                                                                            
  ------------------------ ---------- -------- -------- -------- -------- -------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  **Performance Status**                                                                                                                                                                    
  0                        318        44       303      44.4     297      46.4     274    45.5   253    48.4   211    48.5   185    52.1   163    52.4   140    55.1   105    58.3   87     58.8
  1                        386        53.4     363      53.2     327      51.1     316    52.5   260    49.7   218    50.1   166    46.8   145    46.6   111    43.7   74     41.1   60     40.5
  2                        16         2.21     14       2.05     14       2.19     10     1.66   8      1.53   5      1.15   4      1.13   3      0.96   3      1.18   1      0.56   1      0.68
  3                        3          0.41     2        0.29     2        0.31     2      0.33   2      0.38   1      0.23   0      0      0      0      0      0      0      0      0      0
  **Age**                                                                                                                                                                                   
  Median                   60                  59.9              60                60            60            59.7          60            60.3          61.0          59.0          59.2   
  Interquartile range      13.6                13                13                13            13            13.2          13.0          12.3          12.5          11.9          11.8   
  **Sex**                                                                                                                                                                                   
  Male                     372        51.5     343      50.3     312      48.8     294    48.8   255    48.8   203    46.7   165    46.5   133    42.8   109    42.9   73     40.6   60     40.5
  Female                   351        48.6     339      49.7     328      51.3     308    51.2   268    51.2   232    53.3   190    53.5   178    57.2   145    57.1   107    59.4   88     59.5
  **Smoking history**                                                                                                                                                                       
  Never-smoker             420        58.1     403      59.1     386      60.3     371    61.6   322    61.6   281    64.6   228    64.2   213    68.5   175    68.9   132    73.3   109    73.7
  Ever-smoker              303        41.9     279      40.9     254      39.7     231    38.4   201    38.4   154    35.4   127    35.8   98     31.5   79     31.1   48     26.7   39     26.4
  **T category**                                                                                                                                                                            
  T1a                      333        46.1     318      46.6     309      48.3     283    47     267    51.1   218    50.1   194    54.7   166    53.4   148    58.3   95     52.8   85     57.4
  T1b                      209        28.9     202      29.6     190      29.7     184    30.6   154    29.5   133    30.6   106    29.9   97     31.2   74     29.1   63     35     45     30.4
  T2a                      140        19.4     128      18.8     116      18.1     110    18.3   86     16.4   72     16.6   50     14.1   41     13.2   28     11     19     10.6   17     11.5
  T2b                      31         4.29     26       3.81     20       3.13     18     2.99   12     2.29   11     2.53   4      1.13   6      1.93   3      1.18   3      1.67   1      0.68
  T3a                      10         1.38     8        1.17     5        0.78     7      1.16   4      0.76   1      0.23   1      0.28   1      0.32   1      0.39   0      0      0      0
  **N category**                                                                                                                                                                            
  N0                       581        80.4     557      81.7     535      83.6     498    82.7   452    86.4   360    82.8   314    88.5   268    86.2   229    90.2   165    91.7   139    93.9
  N1                       82         11.3     76       11.1     67       10.5     62     10.3   47     8.99   49     11.3   27     7.61   31     9.97   20     7.87   13     7.22   8      5.41
  N2                       60         8.3      49       7.18     38       5.94     42     6.98   24     4.59   26     5.98   14     3.94   12     3.86   5      1.97   2      1.11   1      0.68
  **Stage**                                                                                                                                                                                 
  IA                       471        65.2     453      66.4     440      68.8     405    67.3   375    71.7   301    69.2   270    76.1   232    74.6   203    79.9   146    81.1   122    82.4
  IB                       88         12.2     84       12.3     78       12.2     76     12.6   65     12.4   50     11.5   39     11     30     9.65   22     8.66   17     9.44   16     10.8
  IIA                      90         12.5     84       12.3     77       12       71     11.8   55     10.5   55     12.6   31     8.73   35     11.3   23     9.06   14     7.78   9      6.08
  IIB                      10         1.38     10       1.47     6        0.94     7      1.16   4      0.76   3      0.69   1      0.28   2      0.64   1      0.39   1      0.56   0      0
  IIIA                     64         8.85     51       7.48     39       6.09     43     7.14   24     4.59   26     5.98   14     3.94   12     3.86   5      1.97   2      1.11   1      0.68
  **Pathologic Subtype**                                                                                                                                                                    
  AIS                      35         4.84     35       5.13     35       5.47     35     5.81   35     6.69   31     7.13   31     8.73   25     8.04   25     9.84   11     6.11   11     7.43
  MIA                      34         4.7      33       4.84     33       5.16     31     5.15   31     5.93   21     4.83   21     5.92   7      2.25   7      2.76   5      2.78   5      3.38
  Lepidic                  125        17.3     118      17.3     116      18.1     107    17.8   106    20.3   78     17.9   75     21.1   68     21.9   63     24.8   45     25     42     28.4
  Acinar                   314        43.4     296      43.4     279      43.6     264    43.9   221    42.3   205    47.1   156    43.9   149    47.9   113    44.5   89     49.4   70     47.3
  Papillary                65         8.99     62       9.09     53       8.28     53     8.8    40     7.65   34     7.82   21     5.92   17     5.47   12     4.72   5      2.78   3      2.03
  Micropapillary           23         3.18     23       3.37     22       3.44     19     3.16   13     2.49   12     2.76   7      1.97   3      0.96   1      0.39   3      1.67   1      0.68
  Solid                    113        15.6     101      14.8     88       13.8     79     13.1   63     12.1   40     9.2    31     8.73   28     9      21     8.27   8      4.44   7      4.73
  Variant                  14         1.94     14       2.05     14       2.19     14     2.33   14     2.68   14     3.22   13     3.66   14     4.5    12     4.72   14     7.78   9      6.08
  **Pathologic grade**                                                                                                                                                                      
  Low                      194        27.4     186      27.8     184      29.4     173    29.4   172    33.8   130    30.9   127    37.1   100    33.7   95     39.3   61     36.8   58     41.7
  Intermediate             379        53.5     358      53.6     332      53       317    53.9   261    51.3   239    56.8   177    51.8   166    55.9   125    51.7   94     56.6   73     52.5
  High                     136        19.2     124      18.6     110      17.6     98     16.7   76     14.9   52     12.4   38     11.1   31     10.4   22     9.09   11     6.63   8      5.76
  **Differentiation**                                                                                                                                                                       
  WD                       248        34.3     240      35.2     237      37       219    36.4   214    40.9   175    40.2   168    47.3   139    44.7   130    51.2   83     46.1   74     50
  MD                       340        47       321      47.1     299      46.7     291    48.3   236    45.1   206    47.4   147    41.4   131    42.1   94     37     86     47.8   64     43.2
  PD                       135        18.7     121      17.7     104      16.3     92     15.3   73     14     54     12.4   40     11.3   41     13.2   30     11.8   11     6.11   10     6.76
  **Solidity**                                                                                                                                                                              
  Non-solid                152        21       144      21.1     144      22.5     128    21.3   127    24.3   87     20     85     23.9   62     19.9   60     23.6   26     14.4   25     16.9
  Part-solid               83         11.5     80       11.7     79       12.3     78     13     76     14.5   74     17     70     19.7   69     22.2   62     24.4   56     31.1   48     32.4
  Solid                    488        67.5     458      67.2     417      65.2     396    65.8   320    61.2   274    63     200    56.3   180    57.9   132    52     98     54.4   75     50.7
  **TDR**                                                                                                                                                                                   
  Median                   33.6                34                35.4              34            39.1          35.7          47.6          37.8          50.5          40.8          52.0   
  Interquartile range      70.1                69.6              72.5              69.8          74.6          67.9          73.5          68.3          71.3          56.4          57.3   
  **SUV**max                                                                                                                                                                                
  Median                   5.10                5.10              4.65              4.95          3.90          4.60          3.30          4.10          3.10          3.40          2.85   
  Interquartile range      7.30                7.30              6.80              7.30          6.35          6.58          5.60          6.38          5.55          5.45          5.00   
  **Adjuvant therapy**                                                                                                                                                                      
  Yes                      271        37.5     255      37.4     219      34.2     227    37.7   160    30.6   170    39.1   100    28.2   108    34.7   60     23.6   52     28.9   30     20.3
  No                       452        62.5     427      62.6     421      65.8     375    62.3   363    69.4   265    60.9   255    71.8   203    65.3   194    76.4   128    71.1   118    79.7

Abbreviations: AIS, Adenocarcinoma-In-Situ; MD, Moderately-Differentiated; MIA, Minimally Invasive Adenocarcinoma; TDR, Tumor shadow-Disappearance Ratio; PD, Poorly-Differentiated; WD, Well-Differentiated

Cox regression analyses {#s3_3}
-----------------------

Univariable Cox regression analyses evaluated the contribution of various clinical, pathological and radiological characteristics on 3-year OS and DFS at baseline and on subsequent 3-year conditional OS and DFS at 1, 2, 3, 4 and 5 years (Table [2](#T2){ref-type="table"}). In terms of conditional OS, performance, stage, pathologic subtype, pathologic grade, differentiation, TDR value, SUVmax and history of adjuvant treatment significantly correlated with subsequent 3-year conditional OS until 3 years after surgery. In contrast, age, sex, smoking history and pathologic pattern group lost their statistical significance at 1 or 2 years after surgery (see Table [3](#T3){ref-type="table"}). In terms of conditional DFS, performance, differentiation, TDR value, SUVmax and history of adjuvant treatment showed significant correlation with subsequent 3-year conditional DFS until 2 years after surgery. Stage, pathologic subtype and pattern group maintained their statistical significance until 1 year after surgery. None of features except age was significantly associated with 3-year DFS estimates at 3 years after surgery

###### Univariable analyses for conditional overall (OS) and disease-free survival (DFS)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                         Baseline        1-year     2-year          3-year     4-year         5-year                                                                                                                                                                                                                                
  ---------------------- --------------- ---------- --------------- ---------- -------------- ---------- -------------- ---------- --------------- ---------- --------------- -------------- --------------- ------- --------------- ------- ---------------- -------- -------------- ------- --------------- ------- ------------- ---------
  Age at diagnosis       1.05\           0.001      1.02\           0.054      1.05\          0.001      1.03\          0.120      1.03\           0.198      1.08\           0.013          1.03\           0.349   1.18\           0.002   1.00\            0.910    1.16\          0.301   0.98\           0.790   1.16\         0.300
                         (1.02-1.08)                (1.00-1.03)                (1.02-1.08)               (0.99-1.08)               (0.99-1.07)                (1.02-1.15)                    (0.97-1.08)             (1.06-1.32)             (0.92-1.08)               (0.88-1.53)            (0.86-1.12)             (0.88-1.53)   

  Performance status                                                                                                                                                                                                                                                                                                                

  0                                                                                                                     \-                         \-                         \-                             \-                      \-                       \-                      \-                      \-                    \-

  1                      4.45\           \< 0.001   2.56\           \< 0.001   4.21\          \< 0.001   2.11\          \< 0.001   4.00\           0.006      2.22\           0.003          3.43\           0.033   2.05\           0.064   3.73\            0.107    1.71\          0.337   0.72\           0.786   1.63\         0.554
                         (2.18-9.22)                (1.84-3.58)                (1.95-9.10)               (1.44-3.08)               (1.49-10.74)               (1.32-3.72)                    (1.10-10.65)            (0.96-4.38)             (0.75-18.54)              (0.57-5.10)            (0.07-7.91)             (0.33-8.09)   

  2                      14.16\          \< 0.001   2.61\           0.066      8.85\          0.006      3.71\          0.013      20.43\          \< 0.001   NA              0.983          15.69\          0.015   NA              0.989   NA               0.9955   NA             0.994   NA                      NA            
                         (4.33-46.31)               (0.94-7.25)                (1.87-42.00)              (1.32-10.90)              (3.91-106.79)                                             (1.72-142.99)                                                                                                                          

  3                      20.9\           0.004      7.67\           \< 0.001   NA             0.99       11.25\         0.001      NA              0.992      39.47\          \< 0.001       NA              0.995   NA                      NA                        NA             0.998   NA                      NA            
                         (2.63-166.08)              (1.86-31.66)                                         (2.70-46.88)                                         (8.82-176.61)                                                                                                                                                         

  Sex                                                                                                                                                                                                                                                                                                                               

  Female                                                                                                                \-                         \-                         \-                             \-                      \-                       \-                      \-                      \-                    \-

  Male                   3.35\           \< 0.001   1.38\           0.033      3.49\          \< 0.001   1.98\          0.084      2.29\           0.044      1.53\           0.431          1.84\           0.215   1.88\           0.490   2.29\            0.257    NA             0.998   0.70\           0.775   NA            0.998
                         (1.83-6.13)                (1.03-1.86)                (1.76-6.89)               (0.91-4.29)               (1.02-5.15)                (0.53-4.42)                    (0.70-4.85)             (0.31-11.25)            (0.55-9.58)                                      (0.06-7.77)                           

  Smoking history                                                                                                                                                                                                                                                                                                                   

  Never-smoker                                                                                                          \-                         \-                         \-                             \-                      \-                       \-                      \-                      \-                    \-

  Ever-smoker            2.50\           0.001      1.34\           0.055      2.42\          0.003      1.95\          0.079      1.70\           0.180      1.84\           0.256          1.17\           0.752   3.15\           0.209   1.44\            0.621    NA             0.998   NA              0.996   NA            0.998
                         (1.47-4.25)                (0.99-1.80)                (1.34-4.38)               (0.93-4.10)               (0.78-3.68)                (0.64-5.25)                    (0.43-3.18)             (0.53-18.96)            (0.34-6.02)                                                                            

  Stage                                                                                                                                                                                                                                                                                                                             

  IA                                                                                                                                               \-                         \-                             \-                      \-                       \-                      \-                      \-                    \-

  IB                     4.32\           \< 0.001   4.22\           \< 0.001   5.13\          \< 0.001   3.41\          0.030      4.46\           0.005      2.78\           0.139          7.34\           0.002   NA              0.996   23.67\           0.006    NA             1.000   7.90\           0.144   NA            1.000
                         (1.92-9.74)                (1.87-9.50)                (2.21-11.89)              (1.14-10.18)              (1.59-12.56)               (0.72-10.78)                   (2.21-25.37)                                    (2.46-227.54)                                    (0.52-35.64))                         

  IIA                    5.67\           \< 0.001   5.86\           \< 0.001   6.23\          \< 0.001   7.85\          \< 0.001   4.45\           0.005      4.61\           0.015          5.87\           0.009   6.43\           0.042   20.69\           0.015    NA             0.998   NA              0.998   NA            0.998
                         (2.65-12.13)               (2.75-12.49)               (2.78-13.94)              (3.18-19.39)              (1.57-12.63)               (1.35-15.80)                   (1.55-22.19)            (1.07-38.72)            (1.82-235.17)                                                                          

  IIB                    15.28\          \< 0.001   16.28\          \< 0.001   19.72\         \< 0.001   NA             0.990      11.13\          0.023      NA              0.998          29.17\          0.002   NA              0.999   NA               0.998    NA                     NA              .       NA            
                         (4.35-53.72)               (4.65-56.98)               5.50-70.74)                                         (1.39-89.35)                                              (3.32-256.51)                                                                                                                          

  IIIA                   14.14\          \< 0.001   14.85\          \< 0.001   8.43\          \< 0.001   7.53\          \< 0.001   6.83\           0.002      NA              0.994          8.09\           0.014   NA              0.998   81.56\           0.001    NA                     NA              .       NA            
                         (6.86-29.12)               (7.26-30.40)               (3.40-20.91)              (2.30-24.63)              (2.05-22.72)                                              (1.52-43.17)                                    (6.43-1034.81)                                                                         

  T category                                                                                                                                                                                                                                                                                                                        

  T1a                                                                                                                   \-                         \-                         \-                             \-                      \-                       \-                      \-                      \-                    \-

  T1b                    92.83\          0.010      3.01\           0.010      3.18\                     3.55\          0.021      3.23\           0.032      1.87\           0.324          1.63\           0.439   1.96\           0.501   2.43\            0.331    NA             0.998   NA              0.996   NA            0.998
                         (1.25-6.40)                (1.33-6.81)                (1.28-7.88)               (1.21-10.38)              (1.10-9.46)                (0.54-6.45)                    (0.47-5.64)             (0.28-13.96)            (0.41-14.55)                                                                           

  T2a                    6.13\           \< 0.001   6.16\           \< 0.001   6.87\          \< 0.001   6.53\          \< 0.001   5.41\           0.003      2.20\           0.282          3.81\           0.035   NA              0.996   6.63\            0.038    NA             0.999   NA              0.996   NA            0.999
                         (2.77-13.57)               (2.78-13.63)               (2.82-16.74)              (2.23-19.14)              (1.76-16.58)               (0.52-9.22)                    (1.10-13.21)                                    (1.11-39.76)                                                                           

  T2b                    18.86\          \< 0.001   18.97\          \< 0.001   18.69\         \< 0.001   14.25\         \< 0.001   9.29\           0.008      6.70\           0.084          11.41\          0.004   26.74\          0.007   NA               0.996    NA             1.000   NA              1.000   NA            1.000
                         (7.62-46.68)               (7.65-46.99)               (6.52-53.60)              (3.38-60.11)              (1.79-48.48)               (0.78-57.93)                   (2.20-59.21)            (2.42-295.27)                                                                                                  

  T3a                    19.69\          \< 0.001   19.29\          \< 0.001   9.62\                     NA             0.991      20.37\          0.007      NA              0.993          NA              0.995   NA              0.999   NA               0.999    NA                     NA                      NA            
                         (5.28-73.51)               (5.19-71.62)               (1.17-78.91)                                        (2.32-179.11)                                                                                                                                                                                    

  N category                                                                                                                                                                                                                                                                                                                        

  N0                                                                                                                    \-                         \-                         \-                             \-                      \-                       \-                      \-                      \-                    \-

  N1                     4.85\           \< 0.001   5.10\           \< 0.001   4.89\          \< 0.001   4.86\          \< 0.001   3.85\           0.003      2.97\           0.095          3.42\           0.038   3.19\           0.302   6.91\            0.030    NA             0.998   NA              0.997   NA            0.998
                         (2.60-9.05)                (2.74-9.49)                (2.52-9.51)               (2.08-11.39)              (1.57-9.43)                (0.83-10.68)                   (1.07-10.90)            (0.35-28.72)            (1.21-39.53)                                                                           

  N2                     7.24\           \< 0.001   7.75\           \< 0.001   4.37\          \< 0.001   5.03\          0.004      3.32\           0.060      NA              0.993          4.13\           0.071   NA              0.995   23.63\           0.001    NA             0.000   NA                      NA            
                         (3.75-13.95)               (4.04-14.89)               (1.86-10.25)              (1.67-15.16)              (0.95-11.60)                                              (0.89-19.22)                                    (3.56-156.85)                                                                          

  Pathologic subtype\*   \-              \< 0.001   \-              \< 0.001                  \< 0.001                  0.005                      0.014                      0.451                          0.040                   0.882                    0.116                   0.977                   0.061                 *0.977*

  Pathologic grade                                                                                                                                                                                                                                                                                                                  

  Low                                                                                                                   \-                         \-                         \-                             \-                      \-                       \-                      \-                      \-                    \-

  Intermediate           5.77\           0.004      8.44\           \< 0.001   4.73\          0.011      4.97\          0.033      5.29\           0.025      3.24\           0.133          3.65\           0.090   3.08\           0.314   3.93\            0.205    NA             0.998   NA              0.996   NA            0.998
                         (1.76-18.88)               (4.29-16.62)               (1.43-15.69)              (1.14-21.75)              (1.23-22.83)               (0.70-15.00)                   (0.82-16.34)            (0.34-27.63)            (0.47-32.72)                                                                           

  High                   15.58\          \< 0.001   11.58\          \< 0.001   12.48\         \< 0.001   13.64\         0.001      8.43\           0.009      4.81\           0.087          5.21\           0.072   NA              0.996   4.40\            0.298    NA             1.000   NA              1.000   NA            1.000
                         (4.65-52.16)               (5.66-23.72)               (3.63-42.88)              (3.00-61.96)              (1.69-42.12)               (0.80-29.03)                   (0.86-31.45)                                    (0.27-71.67)                                                                           

  Differentiation                                                                                                                                                                                                                                                                                                                   

  WD                                                                                                                    \-                         \-                         \-                             \-                      \-                       \-                      \-                      \-                    \-

  MD                     13.22\          \< 0.001   13.74\          \< 0.001   11.43\         \< 0.001   8.19\          0.005      9.97\           0.002      5.92\           0.021          6.80\           0.011   1.85\           0.501   6.80\            0.011    1.85\          0.501   6.21\           0.091   NA            0.998
                         (3.17-55.17)               (3.29-57.32)               (2.72-48.10)              (1.89-35.50)              (2.34-42.42)               (1.31-26.76)                   (1.54-29.90)            (0.31-11.07)            (1.54-29.90)              (0.31-11.07)           (0.75-51.60)                          

  PD                     30.2\           \< 0.001   29.77\          \< 0.001   22.62\         \< 0.001   14.10\         0.001      3.38\           0.225      1.93\           0.591          1.94\           0.590   NA              0.996   1.94\            0.590    NA             0.996   4.70\           0.278   NA            1.000
                         (7.10-128.49)              (7.01-126.47)              (5.18-98.79)              (3.03-65.53)              (0.47-24.09)               (0.18-21.41)                   (0.18-21.49)                                    (0.18-21.49)                                     (0.29-76.97)                          

  TDR values             0.97\           \< 0.001   0.97\           \< 0.001   0.97\          \< 0.001   0.97\          \< 0.001   0.97\           0.001      0.98\           0.044          0.97\           0.012   0.99\           0.578   0.98\            0.119    1.00\          0.866   0.98\           0.454   1.00\         0.866
                         (0.96-0.98)                (0.96-0.98)                (0.95-0.98)               (0.95-0.99)               (0.95-0.99)                (0.96-0.99)                    (0.95-0.99)             (0.97-1.02)             (0.95-1.01)               (0.94-1.06)            (0.94-1.03)             (0.94-1.06)   

  SUVmax                 1.14\           \< 0.001   1.11\           \< 0.001   1.15\          \< 0.001   1.10\          \< 0.001   1.13\           \< 0.001   1.10\           0.008\<0.001   1.12\           0.003   1.07\           0.030   1.10\            0.084    1.05\          0.356   1.28\           0.016   1.07\         0.488
                         (1.09-1.18)                (1.09-1.13)                (1.10-1.19)               (1.07-1.13)               (1.07-1.19)                (1.06-1.14)                    (1.04-1.20)             (1.01-1.14)             (0.99-1.23)               (0.94-1.18)            (1.05-1.56)             (0.89-1.28)   

  Adjuvant therapy                                                                                                                                                                                                                                                                                                                  

  No                                                                                                                    \-                         \-                         \-                             \-                      \-                       \-                      \-                      \-                    \-

  Yes                    4.45\           \< 0.001   11.1\           \< 0.001   5.43\          \< 0.001   7.01\          \< 0.001   6.01\           \< 0.001   6.43\           0.002          6.30\           0.001   4.62\           0.096   16.11\           0.010    NA             0.998   6.03\           0.143   NA            0.998
                         (2.49-7.94)                (7.48-16.47)               (2.75-10.74)              (2.97-16.54)              (2.40-15.03)               (2.01-20.62)                   (2.04-19.43)            (0.76-27.95)            (1.97-131.87)                                    (0.55-66.64)                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Log-Rank test Abbreviations: AIS, Adenocarcinoma-In-Situ; MD, Moderately-Differentiated; MIA, Minimally Invasive Adenocarcinoma; SUVmax, Maximum Standardized Uptake Value; TDR, Tumor shadow-Disappearance Ratio; PD, Poorly-Differentiated; WD, Well-Differentiated

###### Multivariable analyses for conditional overall (OS) and disease-free survival (DFS)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                       Baseline (n=551)   1 yr (*n*=526)   2 yr (*n*=462)     3yr (*n*=343)   4yr (*n*=254)       5yr (*n*=152)                                                                                     
  -------------------- ------------------ ---------------- ------------------ --------------- ------------------- --------------- ------------------- --------- ------------------- --------- --------------------- ---------
  Performance status   2.73 (1.73-4.31)   \<0.001          2.2 (1.31-3.70)    0.003           2.65 (1.37-5.13)    0.00374         2.31 (0.96-5.53)    0.06162   1.82 (0.41-8\       0.4311    0.02 (0-2.23)         0.10596
                                                                                                                                                                .11)                                                

  Stage                1.36 (1.08-1.70)   0.00788          1.25 (0.98-1.59)   0.07455         1.13 (0.81-1.56)    0.4732          1.20 (0.80-1.80)    0.38697   1.95 (1.02-3.73)    0.0431    12.16 (0.84-176.75)   0.0673

  Adjuvant treatment   1.81 (0.83-3.92)   0.1351           2.42 (1.04-5.65)   0.041           3.47 (1.14-10.56)   0.02879         4.38 (1.08-18.36)   0.0431    7.88 (0.73-84.69)   0.0883    1.44 (0.08-27.48)     0.8084

  SUVmax               1.08 (1.03-1.14)   0.00182          1.10 (1.04-1.15)   \<0.00021       1.08 (1.00-1.16)    0.0494955       1.05 (0.95-1.17)    0.33576   0.94 (0.76-1.16)    0.56162   1.19 (0.86-1.64)      0.2953

  Sex                  1.53 (0.60-3.88)   0.37081          2.21 (0.86-5.69)   0.10152         1.74 (0.55-5.56)    0.350496        1.63 (0.43-6.22)    0.4764    1.79 (0.30-10.70)   0.52152   0.91 (0.03-25.13)     0.9544

  Smoking history      1.94 (0.83-4.56)   0.1291           1.38 (0.59-3.22)   0.4531          1.33 (0.43-4.15)    0.62455         1.01 (0.24-4.14)    0.99495   1.45 (0.21-9.98)    0.70859   0                     0.9961
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

                       Baseline (*n*=551)   1 yr (*n*=490)   2 yr (*n*=393)      3yr (*n*=273)   4yr (*n*=203)       5yr (*n*=126)                                                                                   
  -------------------- -------------------- ---------------- ------------------- --------------- ------------------- --------------- -------------------- --------- ------------------- ------- -------------------- -------
  Performance status   1.58 (1.22-2.03)     \<0.001          1.58 (1.16-2.15)    0.004           1.72 (1.09-2.72)    0.019           1.46 (0.70-3.05)     0.311     1.23 (0.43-3.56)    0.698   1.35 (0.26-7.08)     0.721
  TDR                  0.99 (0.98-0.99)     \<0.001          0.99 (0.98-0.99)    \<0.001         0.99 (0.98-1.00)    0.046           1.00 (0.98-1.01)     0.482     1.00 (0.98-1.02)    0.723   1.03 (0.997-1.061)   0.081
  Adjuvant treatment   6.02 (3.86-9.39)     \<0.001          6.68 (4.01-11.12)   \<0.001         9.15 (4.53-18.48)   \<0.001         10.54 (4.03-27.59)   \<0.001   8.15 (2.04-32.66)   0.003   10.95 (1.46-82.43)   0.020
  Stage                1.12 (1.00-1.25)     0.045            1.03 (0.90-1.18)    0.672           0.94 (0.77-1.16)    0.570           0.80 (0.54-1.18)     0.259     1.23 (0.70-2.16)    0.473   2.51 (1.01-6.26)     0.048

Abbreviations: SUVmax, Maximum Standardized Uptake Value; TDR, Tumor shadow-Disappearance Ratio

Statistically significant predictors of 3-year OS and DFS at baseline and subsequent 3-year conditional OS and DFS at 1, 2, 3, 4 and 5 years after surgery were evaluated, fitting multivariable Cox regression models with stepwise regression at each time point (Table [3](#T3){ref-type="table"}). Temporally changing hazard ratios for OS were based on multivariable regression analysis (Figure A2, error bars depict 95% CIs). At baseline, factors significantly associated with poor overall survival were poor performance (HR = 2.73, *p* \< 0.001), higher disease stage (HR = 1.36, *p*-value = 0.0078) and SUVmax (HR = 1.08, *p*-value = 0.0018). Among these variables, performance status and SUVmax remained statistically predictive of subsequent OS at 1 and 2 years after surgery (performance; HR = 2.20, *p*-value = 0.003 at 1-year; HR = 2.65, *p*-value = 0.0037 at 2-year; SUVmax; HR = 1.10, *p*-value = 0.0002 at 1-year; HR = 1.08, *p*-value = 0.0495 at 2-year). At the 3-year time point, there was no statistically significant predictor of subsequent 3-year OS. History of adjuvant treatment, sex and smoking history were not significant predictors of conditional OS at any time.

![Three-year conditional overall survival estimates plotted with cut-point determination are shown, stratified by performance status **a**., stage **b**., history of adjuvant treatment **c**., SUVmax **d**., sex **e**. and history of smoking **f**. The cut-off value for SUVmax was determined as 10.](oncotarget-08-32201-g002){#F2}

Temporally changing hazard ratios for DFS were based on multivariable regression analysis (Figure A3, error bars depict 95% CIs). At baseline, characteristics significantly associated with poor DFS included poor performance (HR = 1.58, *p*-value = 0.0004), low TDR value (HR = 0.99, *p*-value = 0.0001), history of adjuvant treatment (HR = 6.02, *p*-value \< 0.0001) and higher disease stage (HR = 1.12, *p*-value = 0.0451). Among these variables, only history of adjuvant treatment remained predictive of subsequent DFS at 1, 2 and 3 years after surgery (HR = 6.68, 9.15 and 10.54, respectively). Patient performance and TDR value remained significant predictors of subsequent 3-year DFS at the 1- and 2-year mark, but lost their statistical significance by 3 years after surgery (performance; HR = 1.58, *p*-value = 0.0035 at 1 year; HR = 1.72, *p*-value = 0.0190 at 2 years; TDR value; HR = 0.99, *p*-value = 0.0006 at 1 year; HR = 0.99, *p*-value = 0.0457 at 2 years). Disease stage was no longer a significant predictor of subsequent 3-year DFS at any time point except for baseline.

![Three-year conditional disease-free survival estimates plotted with cut-point determination are shown, stratified by performance status **a**., TDR **b**., history of adjuvant treatment **c**. and stage **d**. The cut-off value for TDR was determined as 48.98.](oncotarget-08-32201-g003){#F3}

Stratified conditional survival probability plotting with cut-point determination {#s3_4}
---------------------------------------------------------------------------------

CS analysis was stratified with optimal dichotomizing cut-off value determination according to variables selected at least once during multivariable analysis, with stepwise regression at each time point (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, A4 and A5). In general, 3-year OS and DFS estimates increased for all clinical, pathological and radiological features, and the gap between estimates decreased with a longer follow-up period. For example, 3-year DFS estimates for pathologic grade ranged from 66.18% to 95.36% at baseline, but this range became tighter over time and at year 5 was 87.50% to 96.55% (see Figure A5).

DISCUSSION {#s4}
==========

The single most important prognostic factor in lung adenocarcinoma, the most common histologic type of NSCLC, has been tumor stage \[[@R8], [@R19]\]. However, even in the early stages of disease, prognosis of lung adenocarcinoma varies widely \[[@R20]\], necessitating the establishment of reliable prognostic factors to more accurately predict a broad spectrum of tumor behavior.

In contrast to cumulative survival calculations from traditional survival analysis that provide only a static view of risk without postoperative follow-up information, CS is more relevant to follow-up care because it reflects the change of survival likelihood with increasing duration of follow-up from the time of the initial cancer diagnosis. Leveraging the power of the CS analysis implements more evidence-drive approaches to post-therapy surveillance, particularly focused on long-term survivors over 2-3 years, which means that value of the conditional survival analysis is obviously different from traditional survival analysis and the complementary information of two different survival analyses allows for clinician into more appropriate surveillance.

To our knowledge, this is the first study assessing conditional OS and DFS among patients with lung adenocarcinoma. A few studies were previously publised regarding CS of lung cancer but those did not reflect novel lung adenocarcinoma classifcation scheme from the IASLC/ATS/ERS \[[@R5]--[@R7], [@R21]\] or included small cell lung cancer \[[@R6], [@R7]\] in conditional survival anlysis without emphasis on lung adenocarcinoma. Also, those only presented conditional survival with descriptive way, not or partially elaborating various prognostic factors including clinical, radiological and pathological aspects \[[@R5]--[@R7], [@R21]\]. Another new feature of this study is that we investigated how the effect (or significance) of each factor changed over time, rather than the time-static effect of these, on OS and DFS, which has not been revealed with conventional survival analysis (i.e., cumulative survival). Also, we focused on revealing temporal alteration of prognostic effect of previously well-known independent imaging biomarkers (TDR and SUVmax) and inter-relationship with other prognostic factors. This kind of approach is unique from already reported literatures regarding radiologic prognostic factors.

In this study, we evaluated 3-year conditional survival, facilitating prognostication for survivors who have already passed through high risk period of recurrence. We found clear differences: 3-year OS and DFS of lung adenocarcinoma patients were 92.12% and 75.51% at baseline but improved steadily up to 98.33% and 95.95%, respectively, conditioned on having already survived 1, 2, 3, 4, and 5 years after surgery (See Figure [1](#F1){ref-type="fig"}). Generally, we observed that OS and DFS improved most for patients with various factors known to be correlated with poor prognosis. In addition, the initial gap in OS and DFS at time of surgery between different subgroups based on performance, sex, smoking history, stage, histology and solidity on CT diminished over time, suggesting that the prognostic significance of these factors decreases as time elapses after surgery.

There have been abundant efforts to stratify patients with lung adenocarcinoma, including new classification schemes \[[@R9]\] or noninvasive surrogate imaging biomarkers \[[@R15], [@R22]--[@R26]\]. However, there have been no previous reports comparing prognostication capabilities and temporal changes in the contribution on prognosis after surgery for different factors. At baseline, there were significant associations between evaluated patient characteristics and survival estimates in accordance with previous studies such as age \[[@R27]\], performance \[[@R28]\], sex \[[@R29]\], smoking history \[[@R30]\], stage \[[@R13], [@R19]\], histology \[[@R9]\], grade \[[@R31]\], TDR values \[[@R32], [@R33]\], and SUVmax \[[@R34]\]. However, interestingly, demographic factors lost their statistical significance over time. In contrast, performance status, pathologic factors (stage, subtype, pathologic grade and differentiation), and radiologic factors (TDR and SUVmax) maintained their statistically significant association with 3-year OS until 3 years after surgery. In terms of DFS, none of features except age was significantly associated with CS estimates at 3 years after surgery, but performance, TDR values and SUVmax were statistically associated with subsequent 3-year DFS until 2 years after surgery. From these results, time-independent variables can be differentiated from time-dependent variables, for which further adjustment should be considered for more accurate estimation of prognosis and associated management.

In addition, we performed multivariable regression analysis with various demographic, pathologic and radiologic factors included to discriminate ultimate prognostic factors. Patient performance and SUVmax were independent predictors of subsequent 3-year OS at baseline, 1 and 2 years after surgery. In terms of DFS, TDR value and history of adjuvant treatment were predictive of subsequent 3-year DFS at baseline, 1 and 2 years after surgery. The cut-off values optimally splitting all patients into two groups were determined as 10 and 48.98 for SUVmax and TDR, respectively. These findings based on CS provide theoretical background for clinicians to plan longer period of surveillance following lung adenocarcinoma resection in survivors with preoperatively high SUVmax and low TDR on PET-CT and chest CT, respectively. Actually, many physicians taper follow-up frequency after 3 to 5 years, often with little justification nor evidence based on survival data, for which our study could give the answer to those uncertainties, facilitating a more evidence-based strategy for post-treatment follow-up scheduling based on actual current risk rather than simply on custom or tradition. For instance, if we suppose the condition that subsequent survival probabilities of patients with certain risk factors who survive x years from diagnosis become similar to those of patients without risk factors at diagnosis. Consequently, if clinicians follow up patients without risk factors for y years, patients with high risk factors should be comparably followed for x + y years. Therefore, surveillance strategy for lung adenocarcinoma survivors with preoperatively high SUVmax and low TDR on PET-CT and chest CT, respectively, should be tailored with longer follow-up periods, based on our result.

With respect to tumoral radiologic phenotyping, tumor metabolic information on PET contributed more to overall outcome, whereas TDR on CT contributed to treatment success or failure. Given that metabolic information indicates the degree of tumor aggressiveness \[[@R25], [@R26], [@R35]\] and TDR is associated with the degree of tumor invasion \[[@R35]--[@R38]\], imaging features observed in adenocarcinomas may provide additional prognostic information, assuming that radiologic functional phenotypes from CT and PET reflect tumor behavior.

This study was retrospectively designed with relatively small sample size and limited number of events. However, all patients underwent relatively uniform management including diagnostic work-up, treatment strategy and histopathologic evaluation solely from a single tertiary referral center in Korea, yielding a homogenous Asian study cohort with a relatively large number of subjects. Another limitation of this study is relatively short follow-up time (median 3.8 years) to precisely describe 5-year outcomes. Validation and expansion of our results with large-scale and multiracial data would allow general application.

In conclusion, conditional OS and DFS for patients with operable lung adenocarcinoma improved steadily over time. The initial gap between OS and DFS at time of surgery between different subgroups based on demographic prognostic factors diminished over time, suggesting that the prognostic significance of these factors decreases as time elapses after surgery, whereas the absolute contribution of pathologic and radiologic factors remained. Therefore, tenacious stance of clinicians on surveillance strategy after lung adenocarcinoma resection might be resonable for survivors with preoperatively high SUVmax and low TDR on PET-CT and chest CT, respectively.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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CS

:   Conditional Survival

DFS

:   Disease-Free Survival

FDG

:   18F-fluoro-2-deoxyglucose

IASLC/ATS/ERS

:   International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society

NSCLC

:   Non-small Cell lung Cancer

OS

:   Overall Survival

TDR

:   Tumor-shadow Disappearance Ratio

SUVmax

:   Maximum Standardized Uptake Value
